Side effects of the drug have been found to be minor which include mild gastrointestinal upset, headache, cough, dizziness, etc. These observations, made during several clinical trials, suggest that vildagliptin and other DPP-4 inhibitors may play an important role in the management and preservation of T2DM, particularly being valuable in preventing the development and progression of the disease, which has not been possible till now with any other antidiabetic agents. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.